Grufity logo
Grufity logo
VIR

VIR - Vir Biotechnology Inc Stock Price, Fair Value and News

$10.58-0.23 (-2.13%)
Delayed as of 10 Sep 2026, 04:00 pm ET

VIR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VIR Price Action

Last 7 days

-7.6%

Last 30 days

18.5%

Last 90 days

22.9%

Trailing 12 Months

106.2%

VIR RSI Chart

VIR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VIR Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-7.11

Price/Sales (Trailing)

5.88

EV/EBITDA

-6.27

Price/Free Cashflow

-8.79

VIR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VIR Fundamentals

VIR Revenue

Revenue (TTM)

304.5M

Rev. Growth (Yr)

19.6K%

Rev. Growth (Qtr)

272.95%

VIR Earnings

Earnings (TTM)

-251.7M

Earnings Growth (Yr)

172.17%

Earnings Growth (Qtr)

163.71%

VIR Profitability

Operating Margin

99.99%

EBT Margin

-82.54%

Return on Equity

-25.62%

Return on Assets

-20.72%

Free Cashflow Yield

-11.37%

VIR Investor Care

Shares Dilution (1Y)

21.84%

Diluted EPS (TTM)

-1.85

VIR Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
Revenue & Growth

How Vir Biotechnology Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026-304.5M--
202520.9M19.0M16.9M68.6M
202479.6M78.9M78.6M74.2M
20231.1B490.7M118.8M86.2M
20222.3B2.1B1.9B1.6B
2021331.1M585.9M840.7M1.1B
202010.1M75.1M75.6M76.4M
201911.9M11.7M10.2M8.1M
20184.7M6.7M8.7M10.7M
2017---2.7M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Vir Biotechnology Inc

VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
 CEO
 WEBSITEvir.bio
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES576

Vir Biotechnology Inc Frequently Asked Questions

VIR is the stock ticker symbol of Vir Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Sep 10 2026, market cap of Vir Biotechnology Inc is 1.79 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Sep 10 2026, VIR's PE ratio (Price to Earnings) is -7.11 and Price to Sales (PS) ratio is 5.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIR PE ratio will change depending on the future growth rate expectations of investors.